This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter    Login            

European Commission authorise sedative Dexdor®

The European Commission has granted centralised marketing authorisation for dexdor® (dexmedetomidine), indicated for sedation of adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale 0 to -3).

Dexdor® (dexmedetomidine) is now licensed across all 27 European Union countries.

The active substance of dexdor® is dexmedetomidine, a sedative agent originated by Orion Corporation’s pharmaceutical R&D.

Article continues below this sponsored advert
Cogora InRead Image
Join us at a one-day virtual cardiology event that will allow you to explore the latest advances in cardiovascular care. With the help of an advisory board of cardiology specialists we have put together an agenda tailored to multi-disciplinary teams - each talk is presented by an expert, or panel, who will share knowledge and case studies of relevance

Dexmedetomidine is available with the brand name Precedex® in more than 30 countries outside Europe, including the USA (since 2000) and Japan (since 2004).

The distributor for the product outside Europe is Hospira, under Orion’s license.

Orion Corporation